In Brief
Refine Search
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Pharmaceutical
On Wednesday, the US Food and Drug Administration published a new draft guidance to assist sponsors in developing treatments for stimulant use disorders. 5 October 2023
Pharmaceutical
The government of Colombia plans to overcome patent barriers to HIV treatment and import low-cost generic versions of the HIV medicine dolutegravir without permission from the patent owner, ViiV Healthcare. 5 October 2023
Pharmaceutical
French pharma major Sanofi (Euronext; SAN) has entered into a collaboration with the US subsidiary of global generics leader Israel-based Teva Pharmaceutical Industries (NYSE and TASE: TEVA). 4 October 2023
Biosimilars
The market for biosimilar versions of AbbVie’s mega-blockbuster TNF blocker Humira (adalimumab) is hotting up, with a major price reduction from Boehringer Ingelheim. 4 October 2023
Biotechnology
The UK is in a strong position to become “a global leader in mRNA medicine,” according to a new report by industry cheerleader the BioIndustry Association (BIA). 4 October 2023
Pharmaceutical
Positive results from the T2NOW Phase III trial have demonstrated significant reduction in A1C, a marker of average blood sugar, for patients treated with Forxiga/Farxiga (dapagliflozin) compared to those receiving placebo. 4 October 2023
Pharmaceutical
California-based Vistagen Therapeutics, a company aiming to transform the treatment landscape for anxiety, depression, and other central nervous system (CNS) disorders, has raised $100 million through an underwritten offering of its common stock. 4 October 2023
Pharmaceutical
US pharma major Eli Lilly today revealed that Mike Mason, executive vice president and president of Lilly Diabetes and Obesity, will retire at the end of 2023 after 34 years with the company. 4 October 2023
Biotechnology
US clinical-stage immuno-oncology company ALX Oncology Holdings saw its shares rocket 56% to $7.51 yesterday, as it announced positive clinical results for its lead asset after a previous disappointment. 4 October 2023
Biotechnology
Positive results have been presented from the primary analysis of the ongoing RAINBOWFISH study assessing the efficacy and safety of Evrysdi (risdiplam) in babies with pre-symptomatic spinal muscular atrophy (SMA), aged from birth to six weeks. 4 October 2023
Biotechnology
Asia-Pacific-focused clinical research organization (CRO) Novotech has appointed Judith Ng-Cashin as chief medical officer. 4 October 2023
Pharmaceutical
Danish diabetes care giant Novo Nordisk’s obesity medication Wegovy (semaglutide) will soon be accessible through the National Health Service (NHS) in England, albeit with limited supply. 4 October 2023
Biotechnology
Fred Hassan, an industry veteran behind some of the biggest pharma M&A deals in the past two decades, has been named as chairman of Saghmos Therapeutics. 4 October 2023
Pharmaceutical
The US Food and Drug Administration has updated the emergency use authorization for the COVID-19 vaccine developed by US biotech Novavax. 4 October 2023
Biotechnology
The US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) is set to review data supporting US biotech giant Amgen’s supplemental New Drug Application (sNDA) for the full approval of Lumakras (sotorasib). 4 October 2023
Generics
USA-based drugmaker Viatris has announced a series of divestitures as part of a strategy to narrow the company’s focus. 3 October 2023
Biotechnology
Following discussions with the US Food and Drug Administration (FDA), Japanese pharm major Takeda said it will be working with the agency towards a voluntary withdrawal of Exkivity (mobocertinib) in the USA. 3 October 2023
Biotechnology
The US Food and Drug Administration (FDA) has approved Rivfloza (nedosiran) injection, a once-monthly subcutaneous ribonucleic acid interference (RNAi) therapy, from Danish diabetes care giant Novo Nordisk. 3 October 2023
Biotechnology
UK respiratory disease focussed biotech Synairgen today announced the appointment of Dr Marcin Mankowski as chief medical officer (CMO), effective immediately. 3 October 2023
Pharmaceutical
Shares US radiopharmaceuticals firm POINT Biopharma Global shot up 84% to $12.31 in pre-market activity, on the news of a takeover bid from Eli Lilly. 3 October 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze